Researchers at the Keck School of Medicine of USC report that an experimental drug called cinaciguat reversed several signs of aging in the specialized liver cells of older rats. After two weeks of treatment, levels of amyloid beta, a protein associated with Alzheimer's disease, dropped by half. LDL, the cholesterol commonly called "bad" cholesterol, also returned to levels seen in younger animals. The study appears in the Journal of Biological Chemistry.
The liver's filtering cells, called liver sinusoidal endothelial cells, line tiny blood vessels and contain microscopic openings that let larger molecules reach the hepatocytes that clear them from the body. As animals age, those openings shrink or disappear, so more of these substances stay in circulation. The researchers saw that cinaciguat reopened the pores and improved clearance. Amyloid beta concentrations fell by roughly 50 percent, close to the levels in young rats, while untreated older rats showed no similar change.
LDL was included mainly as a comparison, since its particles are small enough to pass through the openings without relying on them. The team expected little effect on it, but treated rats saw their LDL fall as well. That result led them to a previously unknown chain of signals between the two liver cell types. According to the study, cinaciguat activates an enzyme in the filtering cells that prompts them to release a growth factor called HB-EGF, which in turn changes the surfaces of hepatocytes so they capture more LDL and amyloid beta from the blood. Aging normally disrupts this signaling, and the drug restored it.
The authors frame the work as a possible route to new therapies that act through the liver rather than the brain, where many Alzheimer's drugs have struggled to get past the blood-brain barrier. Lead author Laurie DeLeve noted that epidemiological work already links both aging and liver damage to Alzheimer's risk, which makes the liver a reasonable place to look.
The results so far come only from rats, and the researchers stress that lowering amyloid beta in the blood does not show that brain plaques will decline or that the disease can be prevented. They plan further studies in rats to test whether the blood-level changes translate into measurable protection, and they hope scientists in atherosclerosis research will explore the liver pathway as well.